Physician profile
Deepinder Singh Bal
NPI 1376538207
$7,418.84
in general payments reported to CMS, 2019-2025
22 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,973 · 2020: $441 · 2021: $786 · 2022: $463 · 2023: $151 · 2024: $487 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $706 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $705.87 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $3,952.84 | 2019-2023 | Gardasil 9, Vaxneuvance, Vaqta |
| Novo Nordisk INC | $720.37 | 2019-2024 | Ozempic |
| Glaxosmithkline, LLC. | $601.80 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $256.75 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $248.88 | 2019-2020 | |
| Amgen INC. | $230.22 | 2019-2024 | Repatha |
| Pfizer INC. | $229.45 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $173.58 | 2019-2020 | |
| Allergan, INC. | $152.60 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.03 | 2019-2022 | |
| Amarin Pharma, INC. | $119.51 | 2019 | |
| Axsome Therapeutics, INC. | $117.41 | 2025 | Auvelity |
| Abbott Laboratories | $99.88 | 2019-2024 | Freestyle Insulinx, Freestyle Libre 3 |
| Corcept Therapeutics | $75.26 | 2024 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.32 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $62.42 | 2019-2022 | |
| Eisai INC. | $32.96 | 2021-2022 | |
| Abbvie INC. | $32.45 | 2021 | |
| Exact Sciences Corporation | $31.39 | 2023 | Cologuard Collection Kit |
| Neuronetics, INC. | $25.83 | 2019 | |
| Astellas Pharma US INC | $20.50 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepinder Bal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.